Catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic arrhythmia syndrome, is characterized by polymorphic ventricular tachycardia with physical or emotional stress in patients with a structurally normal heart.
1 It can be a particularly lethal channelopathy, resulting in symptom onset during childhood and cardiac arrest as a frequent presentation.
2 Mutations in the genes encoding the cardiac ryanodine receptor 2 calcium release channel (
RYR2 [OMIM 180902]) or cardiac calsequestrin (
CASQ2 [OMIM 114251]) are implicated in approximately 60% of cases.
3,4 These proteins regulate intracellular calcium homeostasis in myocytes, and disruptions resulting in excessive sarcoplasmic reticulum calcium release are arrhythmogenic.
5 The recommended first-line therapy for CPVT consists of β-blockers,
6 but recurrent events are common despite β-blocker therapy, especially in children, and rates of near-fatal and fatal events remain unacceptably high.
7 The implantable cardioverter defibrillator (ICD) can be useful in patients at high risk of CPVT events, but ICD shocks can trigger catecholamine release, resulting in arrhythmic storm, multiple shocks, and death.
8,9 Left cardiac sympathetic denervation is a promising option for severely affected patients with syncope despite optimal medical therapy, but it is limited to specialized centers.
10,11 To date, randomized clinical trials have not been performed in CPVT and are exceptional in cardiac channelopathy research, as stated in the most recent international expert consensus statement: “randomized and/or blinded studies do not exist in this field”.
6(p1193)